K-numberK243410
Device namesimpli-COLLECT STI Test
ApplicantAbbott Molecular
Product codeQYA
Device classClass II
Decision dateJan 30, 2025
DecisionSubstantially Equivalent
Regulation866.3385
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The simpli-COLLECT STI Test is a home collection system for detecting Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium in self-collected urine and vaginal swab specimens. Patients collect specimens at home using provided kits, ship them to a clinical laboratory, and testing is performed using the Alinity m STI Assay on the automated Alinity m System to aid in diagnosis of sexually transmitted infections.

Technological characteristics

The device uses real-time reverse transcription-PCR (RT-PCR) for nucleic acid detection, compared to the predicate's target capture/transcription-mediated amplification technology. It employs the Alinity m System instrument rather than the Panther System. The assay includes internal controls, negative controls, and positive controls, with results reported as positive, negative, or invalid (versus the predicate's equivocal category). It detects four organisms compared to the predicate's two, and allows a lower minimum user age of 14 years versus 18 years.

Test standards cited

Not stated in this summary.

Substantial equivalence argument

The substantial equivalence argument rests on the fact that there are no changes to the Alinity m STI assay reagents, sample processing, assay procedure, or data reduction compared to the previously cleared K202977, so prior precision, sensitivity, and specificity studies remain valid. The key difference is the collection kit system (simpli-COLLECT) rather than the assay itself. Human factors studies demonstrated lay users can successfully collect and ship specimens with minimal error using the new kits. The predicate device (Simple 2 Test) also uses home-collected specimens shipped to a laboratory for centralized testing, establishing functional equivalence in the specimen collection and transport pathway despite differences in underlying assay technology and organism targets.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →